Hoth Therapeutics to Spotlight HT-001 in Investor-Focused KOL Event Addressing Breakthrough Combating Cancer Treatment Skin Toxicities
Provided By PR Newswire
Last update: Jun 5, 2025
Company Expands IP Portfolio While Advancing Clinical Innovation in Oncology Supportive Care
Case Study and Interim Clinical Trial Results Will Be Discussed
Read more at prnewswire.comNASDAQ:HOTH (10/1/2025, 1:31:06 PM)
1.635
+0.01 (+0.93%)
Find more stocks in the Stock Screener
